Yuhan Corp Preferred (000105) - Net Assets
Based on the latest financial reports, Yuhan Corp Preferred (000105) has net assets worth ₩2.36 Trillion KRW (≈ $1.60 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩3.22 Trillion ≈ $2.18 Billion USD) and total liabilities (₩858.64 Billion ≈ $581.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000105 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩2.36 Trillion |
| % of Total Assets | 73.34% |
| Annual Growth Rate | 5.76% |
| 5-Year Change | 22.03% |
| 10-Year Change | 57.85% |
| Growth Volatility | 4.02 |
Yuhan Corp Preferred - Net Assets Trend (2014–2025)
This chart illustrates how Yuhan Corp Preferred's net assets have evolved over time, based on quarterly financial data. See 000105 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Yuhan Corp Preferred (2014–2025)
The table below shows the annual net assets of Yuhan Corp Preferred from 2014 to 2025. For live valuation and market cap data, see Yuhan Corp Preferred (000105) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩2.36 Trillion ≈ $1.60 Billion |
+9.84% |
| 2024-12-31 | ₩2.15 Trillion ≈ $1.46 Billion |
+8.42% |
| 2023-12-31 | ₩1.98 Trillion ≈ $1.34 Billion |
-1.20% |
| 2022-12-31 | ₩2.01 Trillion ≈ $1.36 Billion |
+3.71% |
| 2021-12-31 | ₩1.94 Trillion ≈ $1.31 Billion |
+4.84% |
| 2020-12-31 | ₩1.85 Trillion ≈ $1.25 Billion |
+11.91% |
| 2019-12-31 | ₩1.65 Trillion ≈ $1.12 Billion |
-0.11% |
| 2018-12-31 | ₩1.65 Trillion ≈ $1.12 Billion |
+2.83% |
| 2017-12-31 | ₩1.61 Trillion ≈ $1.09 Billion |
+7.34% |
| 2016-12-31 | ₩1.50 Trillion ≈ $1.01 Billion |
+9.72% |
| 2015-12-31 | ₩1.36 Trillion ≈ $924.32 Million |
+6.90% |
| 2014-12-31 | ₩1.28 Trillion ≈ $864.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yuhan Corp Preferred's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 85.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩2.19 Trillion | 94.87% |
| Other Components | ₩118.37 Billion | 5.13% |
| Total Equity | ₩2.31 Trillion | 100.00% |
Yuhan Corp Preferred Competitors by Market Cap
The table below lists competitors of Yuhan Corp Preferred ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pacific Pipe Public Company Limited
BK:PAP
|
$51.84 Million |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
$51.85 Million |
|
Star Media Group Bhd
KLSE:6084
|
$51.86 Million |
|
Orient Ceratech Limited
NSE:ORIENTCER
|
$51.87 Million |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
$51.82 Million |
|
Sirios Resources Inc.
V:SOI
|
$51.81 Million |
|
GeneOne Life Science Inc
KO:011000
|
$51.80 Million |
|
Senstar Technologies Ltd
NASDAQ:SNT
|
$51.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yuhan Corp Preferred's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,100,543,104,230 to 2,306,842,780,630, a change of 206,299,676,400 (9.8%).
- Net income of 194,079,171,660 contributed positively to equity growth.
- Dividend payments of 37,481,120,900 reduced retained earnings.
- Share repurchases of 19,999,943,550 reduced equity.
- New share issuances of 35,456,020,200 increased equity.
- Other factors increased equity by 34,245,548,990.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩194.08 Billion | +8.41% |
| Dividends Paid | ₩37.48 Billion | -1.62% |
| Share Repurchases | ₩20.00 Billion | -0.87% |
| Share Issuances | ₩35.46 Billion | +1.54% |
| Other Changes | ₩34.25 Billion | +1.48% |
| Total Change | ₩- | 9.82% |
Book Value vs Market Value Analysis
This analysis compares Yuhan Corp Preferred's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.56x to 2.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩25980.93 | ₩66600.00 | x |
| 2018-12-31 | ₩26767.73 | ₩66600.00 | x |
| 2019-12-31 | ₩26904.01 | ₩66600.00 | x |
| 2020-12-31 | ₩30079.63 | ₩66600.00 | x |
| 2021-12-31 | ₩28584.38 | ₩66600.00 | x |
| 2022-12-31 | ₩28206.83 | ₩66600.00 | x |
| 2023-12-31 | ₩26868.55 | ₩66600.00 | x |
| 2024-12-31 | ₩28464.98 | ₩66600.00 | x |
| 2025-12-31 | ₩31336.25 | ₩66600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yuhan Corp Preferred utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.41%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.88%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.40x
- Recent ROE (8.41%) is above the historical average (6.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 7.13% | 8.94% | 0.63x | 1.27x | ₩-36.52 Billion |
| 2015 | 9.25% | 11.17% | 0.60x | 1.38x | ₩-10.23 Billion |
| 2016 | 10.77% | 12.21% | 0.65x | 1.37x | ₩11.59 Billion |
| 2017 | 6.81% | 7.46% | 0.70x | 1.31x | ₩-50.96 Billion |
| 2018 | 3.50% | 3.78% | 0.70x | 1.32x | ₩-106.69 Billion |
| 2019 | 2.43% | 2.70% | 0.70x | 1.29x | ₩-124.62 Billion |
| 2020 | 10.48% | 11.90% | 0.68x | 1.30x | ₩8.75 Billion |
| 2021 | 5.32% | 6.08% | 0.69x | 1.28x | ₩-90.10 Billion |
| 2022 | 4.79% | 5.36% | 0.72x | 1.25x | ₩-103.44 Billion |
| 2023 | 6.87% | 7.33% | 0.77x | 1.21x | ₩-62.17 Billion |
| 2024 | 3.37% | 3.42% | 0.70x | 1.40x | ₩-139.37 Billion |
| 2025 | 8.41% | 8.88% | 0.68x | 1.40x | ₩-36.61 Billion |
Industry Comparison
This section compares Yuhan Corp Preferred's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $182,431,660,992
- Average return on equity (ROE) among peers: 4.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yuhan Corp Preferred (000105) | ₩2.36 Trillion | 7.13% | 0.36x | $51.83 Million |
| Dongwha Pharm.Co.Ltd (000020) | $297.40 Billion | 3.39% | 0.25x | $97.49 Million |
| Yuhan Corp. (000100) | $519.03 Billion | 9.81% | 0.47x | $3.90 Billion |
| Yuyu Pharma (000220) | $128.69 Billion | -1.72% | 0.50x | $43.48 Million |
| Yuyu Pharma Inc (000225) | $120.36 Billion | -5.97% | 0.65x | $14.47 Million |
| Yuyu Pharma Inc (000227) | $86.87 Billion | 4.63% | 0.56x | $42.09 Million |
| Ildong Holdings Co Ltd (000230) | $55.81 Billion | 8.24% | 2.38x | $53.57 Million |
| Samil Pharm (000520) | $54.41 Billion | 1.08% | 0.83x | $101.43 Million |
| Donga Socio Holdings (000640) | $266.72 Billion | 7.48% | 1.59x | $367.37 Million |
| Jw Pharmac (001060) | $112.60 Billion | 9.51% | 2.66x | $416.42 Million |
About Yuhan Corp Preferred
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more